Ministerial talks for the Trans-Pacific Partnership (TPP) collapsed in Maui last month when trade ministers sparred over issues including monopolies for biotech drugs, which include many cancer treatments. Talks resumed this weekend in Atlanta, where negotiators are reportedly exploring a tweaked approach to the impasse over biologics. But the approach, which may consider introducing a period of post-marketing surveillance in a system analogous to Japanese law, is an illusion, not an improvement. It is a repackaging of the same harmful idea already rejected by many countries.
In other words, 5 + 3 still makes 8 years exclusivity.